Please login to the form below
olesoxime
This page shows the latest olesoxime news and features for those working in and with pharma, biotech and healthcare.
Roche gains EU PRIME status for Spinraza rival
Prior treatment could include olesoxime, an experimental drug Roche acquired as part of its takeover of Trophos three years ago that was abandoned earlier this year after a failed phase 2
Latest news
-
Roche buys rare disease firm Trophos in €470m deal
The French company formerly had an alliance with Actelion, but the latter withdrew from the collaboration after olesoxime failed a trial in amyotrophic lateral sclerosis in 2011. ... Olesoxime is thought to work by preserving the integrity of
-
Actelion net revenue up 18 per cent for Q2
The company's lead compound, olesoxime, is currently in a phase III trial testing its efficacy in the treatment of ALS.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch table for January 2015
Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.
-
Pharma deals during January 2015
A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
